- Home
- CNX vs AXSM Comparison
CNX vs AXSM Comparison
Compare CNX & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNX
- AXSM
- Stock Information
- Founded
- CNX 1860
- AXSM 2012
- Country
- CNX United States
- AXSM United States
- Employees
- CNX N/A
- AXSM N/A
- Industry
- CNX Oil & Gas Production
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- CNX Energy
- AXSM Health Care
- Exchange
- CNX Nasdaq
- AXSM Nasdaq
- Market Cap
- CNX 5.4B
- AXSM 4.4B
- IPO Year
- CNX 1999
- AXSM 2015
- Fundamental
- Price
- CNX $38.17
- AXSM $93.18
- Analyst Decision
- CNX Hold
- AXSM Strong Buy
- Analyst Count
- CNX 12
- AXSM 14
- Target Price
- CNX $28.09
- AXSM $124.93
- AVG Volume (30 Days)
- CNX 2.8M
- AXSM 518.8K
- Earning Date
- CNX 10-24-2024
- AXSM 11-12-2024
- Dividend Yield
- CNX N/A
- AXSM N/A
- EPS Growth
- CNX N/A
- AXSM N/A
- EPS
- CNX 3.15
- AXSM N/A
- Revenue
- CNX $1,369,239,000.00
- AXSM $338,457,000.00
- Revenue This Year
- CNX $8.43
- AXSM $40.67
- Revenue Next Year
- CNX $15.20
- AXSM $69.27
- P/E Ratio
- CNX $12.12
- AXSM N/A
- Revenue Growth
- CNX N/A
- AXSM 51.47
- 52 Week Low
- CNX $19.07
- AXSM $56.66
- 52 Week High
- CNX $40.08
- AXSM $105.00
- Technical
- Relative Strength Index (RSI)
- CNX 62.03
- AXSM 63.56
- Support Level
- CNX $37.98
- AXSM $88.74
- Resistance Level
- CNX $40.08
- AXSM $105.00
- Average True Range (ATR)
- CNX 1.21
- AXSM 3.35
- MACD
- CNX 0.09
- AXSM 0.92
- Stochastic Oscillator
- CNX 70.25
- AXSM 59.25
About CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.